RELiZORB Hydrolyzes Fats Prior to Ingestion
RELiZORB is a digestive enzyme cartridge that contains iLipase® and connects in-line with enteral feeding systems. Lipase is covalently bound to small white beads inside the RELiZORB cartridge and is retained in the cartridge during use by two filters. Enteral formula flows through, allowing for fats to be hydrolyzed and the immediate delivery of absorbable fatty acids and monoglycerides to the gastrointestinal (GI) tract.
RELiZORB is proven to hydrolyze available fats,* including medium-chain triglycerides (MCTs) and long-chain triglycerides (LCTs).1
- LCTs are complex and contain essential fatty acids
- Compared to MCTs, LCTs are harder to hydrolyze but provide ~10% more calories
- RELiZORB is intended to provide continuous fat hydrolysis during enteral feeding
*
*Greater than 90% of available fats hydrolyzed in most enteral formulas tested, including Nutren 1.5, Impact Peptide 1.5,
Peptamen 1.5, Peptamen AF, and Nutren 1.0. Percentage of fat hydrolysis is estimated based on label claim for content, calculated using 500 mL of formula with a pump rate of 120 mL/hr.
Please see full list of compatible formulas.
RELiZORB resources are available to support healthcare professionals
Below you can find links to resources (for both inpatient and outpatient services) designed to help your practice or hospital.
References
- Freedman S. Options for Addressing Exocrine Pancreatic Insufficiency in Patients Receiving Enteral Nutrition Supplementation. Am J Manag Care. 2017 Jul;23(12 Suppl):S220-S228.